Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
4.980
+0.320 (6.87%)
At close: Dec 20, 2024, 4:00 PM
5.16
+0.18 (3.61%)
After-hours: Dec 20, 2024, 7:59 PM EST
Vivos Therapeutics Employees
As of December 31, 2023, Vivos Therapeutics had 123 total employees, including 114 full-time and 9 part-time employees. The number of employees decreased by 40 or -24.54% compared to the previous year.
Employees
123
Change (1Y)
-40
Growth (1Y)
-24.54%
Revenue / Employee
$118,545
Profits / Employee
-$102,179
Market Cap
24.08M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 123 | -40 | -24.54% |
Dec 31, 2022 | 163 | -4 | -2.40% |
Dec 31, 2021 | 167 | 69 | 70.41% |
Dec 31, 2020 | 98 | 14 | 16.67% |
Dec 31, 2019 | 84 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Allurion Technologies | 504 |
Co-Diagnostics | 155 |
PolyPid | 62 |
Cara Therapeutics | 55 |
Longeveron | 24 |
GeoVax Labs | 17 |
NeuroOne Medical Technologies | 16 |
iBio, Inc. | 16 |
VVOS News
- 5 weeks ago - Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call - GlobeNewsWire
- 2 months ago - Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association - GlobeNewsWire
- 3 months ago - Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - GlobeNewsWire
- 4 months ago - Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 months ago - Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call - GlobeNewsWire
- 6 months ago - Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model - GlobeNewsWire